A Real-world Long-term Safety and Immunogenicity Study of Olipudase Alfa Therapy in Pediatric Patients Less Than 2 Years of Age With Acid Sphingomyelinase Deficiency (ASMD)

Study of Long-Term Safety and Immune Response to Enzyme Replacement Therapy in Young Children With Acid Sphingomyelinase Deficiency

Age
2 years or below
Gender
All
Phase
N/A
Participants needed
10
Locations
6
Find a study site near you

Study Overview

US, multicenter, cohort, open label observational study with primary data collection. Ancillary protocol-specified procedures to address the study objectives (eg, assessment of ADA) may be considered outside the standard of care for acid sphingomyelinase deficiency (ASMD), but the study methodology remains non-interventional, as the additional collection of data from participants will not dictate treatment. The total overall study duration will be 5 years. The follow-up period will be a minimum of 1 year to a maximum of 3 years. The enrollment period will be up to 4 years, to allow a minimum of 1 year of follow-up for the last participant enrolled.

Study Details

This is a hybrid study design.
Patients need not travel to existing study sites in order to enroll.

Eligibility Criteria

You may be eligible for this study if you meet the following criteria:

  • Conditions: Niemann-Pick Diseases, Acid Sphingomyelinase Deficiency
  • Age: 2 years or below
  • Gender: All

Inclusion Criteria:

  • The participant must have ASMD type A/B or B and must be <2 years of age at the time of treatment initiation, OR ASMD type A (without age restriction).
  • The participant must weigh ≥ 2 kg [The United States Prescribing Information (USPI)] for olipudase alfa specifies this minimum weight for infants receiving olipudase alfa).
  • The participant must have documented ASMD, as determined in peripheral leukocytes, cultured fibroblasts, or lymphocytes and/or by genotype determination.
  • Signed informed consent must be provided by the participant's parent(s)/legal guardian(s), including compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol. The signed ICF must be provided before any protocol-related procedures are performed.
  • The participant is eligible to start olipudase alfa enzyme replacement therapy or has received the first dose (and no more) of olipudase alfa, and has retrievable clinical, laboratory, and ADA data.

Exclusion Criteria:

  • The participant has received an investigational drug within 30 days or 5 drug half-lives before signature of the ICF and study enrollment.
  • The participant is not suitable for participation for reasons determined by the Investigator, including medical or clinical conditions, or potential risk of noncompliance with study procedures.
  • The participant is an immediate family member of employees of the study site or other individuals directly involved in study conduct, in conjunction with Section 1.61 of ICH-GCP Ordinance E6.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

The purpose of this research study is to learn about the long-term safety and immune response to enzyme replacement therapy in children with acid sphingomyelinase deficiency (ASMD). This study is for children with certain types of ASMD, including infants and very young children starting this treatment.

Participants will receive enzyme replacement therapy as part of their usual care. The study will collect health information and may include some study-specific checks that are not part of standard care, such as testing for anti-drug antibodies (proteins the body may make against the treatment). This is an observational study, meaning the study does not decide or change the child’s treatment.

Who can participate:
Children with ASMD may be able to participate if they:

  • Have ASMD type A/B or type B and are under 2 years old when they start treatment, or have ASMD type A (any age)
  • Weigh at least 2 kg
  • Have ASMD confirmed by lab testing and/or genetic testing
  • Are eligible to start enzyme replacement therapy or have already received the first dose (and no more than one dose)
  • Have clinical and laboratory information (including anti-drug antibody data) that can be retrieved

Study timeline and visits:
Participation lasts 1 to 3 years. The overall study will run for 5 years. Children do not need to travel to existing study sites to enroll.

Updated on 15 Sep 2026. Study ID: NCT06192576

Find a study site near you

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
United States Only: Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Email

View email

Phone

Phone country flag

View phone
Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Other language

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.